Samir K Gupta1, James E Slaven2, Lisa M Kamendulis3, Ziyue Liu2. 1. Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN, USA sgupta1@iu.edu. 2. Department of Biostatistics, Indiana University School of Medicine and School of Public Health, Indianapolis, IN, USA. 3. Department of Environmental Health, Indiana University, Bloomington, IN, USA.
Abstract
OBJECTIVES: The HIV NNRTI rilpivirine is being evaluated as a possible agent for HIV pre-exposure prophylaxis. We have recently shown that the NNRTI efavirenz may impair endothelial function assessed as flow-mediated dilation (FMD), but whether this impairment is also found with rilpivirine is unknown. We sought to compare cardiovascular risk profiles between efavirenz and rilpivirine in healthy volunteers. METHODS: We performed a prospective, randomized, open-label trial in 40 HIV-uninfected healthy volunteers who were randomized 1: 1 to either efavirenz or rilpivirine. Vascular indices, metabolic parameters, inflammatory biomarkers and oxidative stress were measured before and after 4 weeks of treatment. This study is registered at ClinicalTrials.gov (NCT01585038). RESULTS: There were no significant differences in 4 week mean (SD) changes in FMD between efavirenz and rilpivirine [0.089 (3.65)% versus 0.63 (2.42)%; P = 0.77]. There were also no significant differences in 4 week changes in high-sensitivity C-reactive protein, IL-6, soluble vascular cell adhesion molecule-1, HDL-cholesterol, triglycerides or homeostasis model assessment-insulin resistance. However, efavirenz led to significant increases in total cholesterol [19.39 (23.9) versus -5.78 (16.5) mg/dL; P < 0.001], LDL-cholesterol [13.29 (19.5) versus -2.24 (13.4) mg/dL; P = 0.009] and F2-isoprostanes [92.7 (178.6) versus -101.4 (215.7) pg/mL; P = 0.019] compared with rilpivirine. Two participants from each study group discontinued prematurely for adverse events. CONCLUSIONS: There were no significant differences in the changes in endothelial function over 1 month between the efavirenz and rilpivirine groups, although efavirenz had worse lipid changes compared with rilpivirine. Longer-term studies are required for confirmation.
RCT Entities:
OBJECTIVES: The HIV NNRTI rilpivirine is being evaluated as a possible agent for HIV pre-exposure prophylaxis. We have recently shown that the NNRTI efavirenz may impair endothelial function assessed as flow-mediated dilation (FMD), but whether this impairment is also found with rilpivirine is unknown. We sought to compare cardiovascular risk profiles between efavirenz and rilpivirine in healthy volunteers. METHODS: We performed a prospective, randomized, open-label trial in 40 HIV-uninfected healthy volunteers who were randomized 1: 1 to either efavirenz or rilpivirine. Vascular indices, metabolic parameters, inflammatory biomarkers and oxidative stress were measured before and after 4 weeks of treatment. This study is registered at ClinicalTrials.gov (NCT01585038). RESULTS: There were no significant differences in 4 week mean (SD) changes in FMD between efavirenz and rilpivirine [0.089 (3.65)% versus 0.63 (2.42)%; P = 0.77]. There were also no significant differences in 4 week changes in high-sensitivity C-reactive protein, IL-6, soluble vascular cell adhesion molecule-1, HDL-cholesterol, triglycerides or homeostasis model assessment-insulin resistance. However, efavirenz led to significant increases in total cholesterol [19.39 (23.9) versus -5.78 (16.5) mg/dL; P < 0.001], LDL-cholesterol [13.29 (19.5) versus -2.24 (13.4) mg/dL; P = 0.009] and F2-isoprostanes [92.7 (178.6) versus -101.4 (215.7) pg/mL; P = 0.019] compared with rilpivirine. Two participants from each study group discontinued prematurely for adverse events. CONCLUSIONS: There were no significant differences in the changes in endothelial function over 1 month between the efavirenz and rilpivirine groups, although efavirenz had worse lipid changes compared with rilpivirine. Longer-term studies are required for confirmation.
Authors: Mary C Corretti; Todd J Anderson; Emelia J Benjamin; David Celermajer; Francois Charbonneau; Mark A Creager; John Deanfield; Helmut Drexler; Marie Gerhard-Herman; David Herrington; Patrick Vallance; Joseph Vita; Robert Vogel Journal: J Am Coll Cardiol Date: 2002-01-16 Impact factor: 24.094
Authors: Leigh Anne Redhage; Ayumi Shintani; David W Haas; Nkiruka Emeagwali; Milica Markovic; Ikwo Oboho; Christopher Mwenya; Husamettin Erdem; Edward P Acosta; Jason D Morrow; Todd Hulgan Journal: HIV Clin Trials Date: 2009 May-Jun
Authors: Calvin J Cohen; Jaime Andrade-Villanueva; Bonaventura Clotet; Jan Fourie; Margaret A Johnson; Kiat Ruxrungtham; Hao Wu; Carmen Zorrilla; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven Journal: Lancet Date: 2011-07-16 Impact factor: 79.321
Authors: Todd Hulgan; Jason Morrow; Richard T D'Aquila; Stephen Raffanti; Michael Morgan; Peter Rebeiro; David W Haas Journal: Clin Infect Dis Date: 2003-11-19 Impact factor: 9.079
Authors: Marshall J Glesby; Donald R Hoover; Farbod Raiszadeh; Irene Lee; Qiuhu Shi; Ginger Milne; Stephanie C Sanchez; Wei Gao; Robert C Kaplan; Jason D Morrow; Kathryn Anastos Journal: Antivir Ther Date: 2009
Authors: Daniel A Duprez; Jacqueline Neuhaus; Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Daniel Nixon; Nicholas I Paton; Ronald J Prineas; James D Neaton Journal: PLoS One Date: 2012-09-10 Impact factor: 3.240
Authors: Samir K Gupta; Changyu Shen; Sharon M Moe; Lisa M Kamendulis; Mitchell Goldman; Michael P Dubé Journal: PLoS One Date: 2012-09-20 Impact factor: 3.240